Immune Checkpoint Inhibitors and Atherosclerotic Plaque Volume

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-01

Study Completion Date

2022-08-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, investigators plan to test whether Immune Checkpoint Inhibitor (ICI) treatment leads to an accelerated progression of atherosclerosis in patients with lung cancer. Atherosclerosis is an immune-mediated inflammatory disease and these same checkpoints being targeted for cancer are critical negative regulators of atherosclerosis in animal and cellular models. Aortic plaque progression will be compared between cases (on ICI) and controls from pre-ICI to post-ICI among patients with non-small cell lung cancer. Groups will be matched for age, cancer type and stage and cardiovascular risk factors. Traditional markers of cardiovascular (CVD) risk and cancer-specific factors (ICI mono- and combination therapy, number of cycles, occurrence of immune-related adverse events, chest radiation, steroid use) will be associated with the change in aortic plaque volume.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Multicenter Cohort Study to Validate Four Groups of Biomarkers for Assessing Lung Cancer Risk Among Patients With Atheromatous Cardiovascular Disease in a Screening Pathway

NCT06387017

RECRUITING NA

Detection of Early Metastases in Patients With Stage I Non-small Cell Lung Cancer

NCT00003006

Lung Cancer

COMPLETED

A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China

NCT07316062

Non-Small-Cell Lung

NOT_YET_RECRUITING

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients

NCT04566432

Lung Neoplasms Lung Cancer, Nonsmall Cell Adenocarcinoma of Lung +1 more

RECRUITING

Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator

NCT04352335

Advanced Lung Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Cases:

* Subjects with non-small cell lung cancer treated with Immune Checkpoint Inhibitors.
* Available contrast enhanced CT scans of the chest both immediately pre-ICI (\< 1 month) and latest follow-up.

Controls:

* Subjects with non-small cell lung cancer, age, cancer stage and cardiovascular risk factor matched to cases.
* Available contrast enhanced CT scan of the chest at two time-points at a similar interval between scans as the cases.